News
CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...
The European Medicines Agency’s human medicines committee has recommended that BeOne Medicines’ Tevimbra (tislelizumab) be ...
4d
Pharmaceutical Technology on MSNBeOne Medicines’ BTK degrader gains EMA PRIME designation
The designation was based on the therapy’s novel mechanism and data showing its anti-tumour activity in B-cell malignancies.
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Medicines Agency (EMA) has ...
8d
Pharmaceutical Technology on MSNGilead wins positive European approval opinion for twice-yearly HIV injection
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Gilead ...
Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent ...
AGC Biologics’ Milan site achieved its 10th product approval from a major regulatory body after the EU granted marketing authorization for AUCATZYL®.
The EU's medicines regulator said it would approve the treatment for a limited group of patients, citing concerns over side effects ...
Moderna (Nasdaq: MRNA) has secured European clearance for its latest version of Spikevax (elasomeran) for individuals aged ...
Lilly’s appeal of an earlier, negative recommendation from a key EMA committee has worked out in its favor, and puts the drug ...
European regulators said that Eli Lilly’s Alzheimer’s treatment Kisunla should be approved for select patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results